



Phebra Pty Ltd

Chernwatch: 25-9466 Version No: 3.1.1.1 Safety Data Sheet according to WHS and ADG requirements Chemwatch Hazard Alert Code: 2

Issue Date: 27/06/2017 Print Date: 07/03/2018 S.GHS.AUS.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

Product name	Proladone®, Oxycodone 30mg Suppositories	
Synonyms	Not Available	
Other means of identification	Not Available	
Relevant identified uses of the substance or mixture and uses advised against		

Relevant identified uses Proladone® Suppositories are indicated for; Semisynthetic narcotic analgesic. Relief of post-operative pain following a wide range of major operative procedures such as major orthopaedic, abdominal, gynaecological and thoracic surgery and for the relief of pain in malignant disease.

Details of the supplier of the safety data sheet

Registered company name	Phebra
Address	19 Orion Road Lane Cove West NSW 2066 Australia
Telephone	+61 2 9420 9199 1800 720 020
Fax	+61 2 9420 9177
Website	www.phebra.com
Email	info@phebra.com

Emergency telephone number

0,1	
Association / Organisation	Not Available
Emergency telephone numbers	+61 401 264 004
Other emergency telephone numbers	N/A

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

Poisons Schedule	S8
Classification ^[1]	Specific target organ toxicity - repeated exposure Category 2
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex VI
Label elements	
Hazard pictogram(s)	
SIGNAL WORD	WARNING
Hazard statement(s)	
H373	May cause damage to organs through prolonged or repeated exposure.
Precautionary statement(s) Pr	revention
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
Precautionary statement(s) Re	esponse
	Get medical advice/attention if you feel unwell.

P501 Dispose of contents/container in accordance with local regulations.

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name			
63-42-3	47.6	alpha-lactose			
9005-25-8	30.8	starch			
Not Available	14.1	hard fat triglyceride esters			
9000-69-5	2.9	pectin			
76-42-6	2.1	Oxycodone			
Not Available	1.7	vinylpyrrolidone homopolymer			
557-04-0	0.8	magnesium stearate			

SECTION 4 FIRST AID MEASURES

Description of first aid measures

Eye Contact	If this product comes in contact with eyes: Wash out immediately with water. If irritation continues, seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary.
Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice.

Indication of any immediate medical attention and special treatment needed

Treat symptomatically for a narcotic analgesic.

A vigorous program of symptomatic and supportive therapy has saved many victims of poisoning. The single most important element in therapy is the correction of anoxia by all available means: the maintenance of a patent airway, the administration of oxygen, the use of artificial respiration, and the injection of specific narcotic antagonists such as nalorphine, levallorphan or naloxone promptly antagonises the respiratory depression, coma and hypotension from overdoses of morphine, codeine, all semi-synthetics and almost all synthetic narcotics.

GOSSELIN et al: Clinical Toxicology of Commercial Products.

In fully conscious patients, remove swallowed poison by thorough gastric lavage and emesis. The chances of removing a significant amount of the drug are better if treatment is started within the first two hours. If the patient is unconscious or depressed, emesis is contraindicated and the dangers of gastric lavage are not justified. DREISBACH AND ROBERTSON: Handbook of Poisoning, Appleton & Lange

Treat symptomatically.

SECTION 5 FIREFIGHTING MEASURES

Extinguishing media

There is no restriction on the type of extinguisher which may be used.

Use extinguishing media suitable for surrounding area.

Special hazards arising from the substrate or mixture

Fire Incompatibility	Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
Advice for firefighters	
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. Slight hazard when exposed to heat, flame and oxidisers.
Fire/Explosion Hazard	 Non combustible. Not considered a significant fire risk, however containers may burn. Decomposition may produce toxic fumes of: , carbon dioxide (CO2) , other pyrolysis products typical of burning organic material.

Issue Date: 27/06/2017 Print Date: 07/03/2018

Proladone®, Oxycodone 30mg Suppositories

	May emit clouds of acrid smoke May emit poisonous fumes. May emit corrosive fumes.
HAZCHEM	Not Applicable

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	 Clean up all spills immediately. Secure load if safe to do so. Bundle/collect recoverable product. Collect remaining material in containers with covers for disposal.
Major Spills	 Minor hazard. Clear area of personnel. Alert Fire Brigade and tell them location and nature of hazard. Control personal contact with the substance, by using protective equipment as required. Prevent spillage from entering drains or water ways. Contain spill with sand, earth or vermiculite. Collect recoverable product into labelled containers for recycling. Absorb remaining product with sand, earth or vermiculite and place in appropriate containers for disposal.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps. Safe handling DO NOT enter confined spaces until atmosphere has been checked. • DO NOT allow material to contact humans, exposed food or food utensils. Avoid contact with incompatible materials. • When handling, DO NOT eat, drink or smoke. NOTE: Special security requirements may be mandated under Federal/State Regulation(s). Store in original containers. Store in vault fitted with warning devices or detectors recommended by various Federal/State authorities. ۲ Store in vault used only for the purpose of storage of drugs of addiction. Vault must be locked at all times except when the materials stored therein are required. Other information Keep storage area free from debris, wastes and combustibles. Þ. Keep dry. Keep containers securely sealed. ۶ Store away from incompatible materials.

Conditions for safe storage, including any incompatibilities

Suitable container	 Packaging as recommended by manufacturer. Check that containers are clearly labelled. Tamper-proof containers. Polyethylene or polypropylene containers. Metal drum with sealed plastic liner.
Storage incompatibility	Avoid reaction with oxidising agents

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	starch	Starch	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	magnesium stearate	Stearates	10 mg/m3	Not Available	Not Available	Not Available

EMERGENCY LIMITS

Ingredient	Material name	TEEL-1		TEEL-2	TEEL-3	
starch	Thyodene; (Amylodextrin)	30 mg/m3		330 mg/m3	2,000 mg/m3	
Ingredient	Original IDLH	Original IDLH		Revised IDLH		
alpha-lactose	Not Available	Not Available		Not Available		

starch	Not Available	Not Available
hard fat triglyceride esters	Not Available	Not Available
pectin	Not Available	Not Available
Oxycodone	Not Available	Not Available
vinylpyrrolidone homopolymer	Not Available	Not Available
magnesium stearate	Not Available	Not Available

Exposure controls

Appropriate engineering controls	Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the risk. Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure. General exhaust is adequate under normal operating conditions.
Personal protection	
Eye and face protection	 Safety glasses with side shields Chemical goggles. Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. (CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent] No special equipment required due to the physical form of the product. Safety glasses with side shields. Chemical goggles. Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly.
Skin protection	See Hand protection below
Hands/feet protection	 Wear chemical protective gloves, e.g. PVC. Wear safety footwear or safety gumboots, e.g. Rubber Wear general protective gloves, eg. light weight rubber gloves. No special equipment required due to the physical form of the product.
Body protection	See Other protection below
Other protection	 ▶ Overalls. ▶ P.V.C. apron. ▶ Barrier cream.
Other protection	 ▶ Skin cleansing cream. ▶ Eye wash unit.

Respiratory protection

- Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
- The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
- Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.
- Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.
- ▶ Use approved positive flow mask if significant quantities of dust becomes airborne.
- Try to avoid creating dust conditions.

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Appearance	Proladone® Suppositories are off-white, ovoid wax coated suppositories;does not mix with water.		
Physical state	Manufactured	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available

Melting point / freezing point (°C)	Not Applicable	Viscosity (cSt)	Not Applicable
Initial boiling point and boiling range (°C)	Not Applicable	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Applicable	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Applicable
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Applicable
Vapour pressure (kPa)	Not Applicable	Gas group	Not Available
Solubility in water (g/L)	Immiscible	pH as a solution (1%)	Not Applicable
Vapour density (Air = 1)	Not Applicable	VOC g/L	Not Available

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on toxicological effects

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.		
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual. Morphine and other analgesics cause nausea, vomiting, constipation, drowsiness and confusion. Urination can be difficult, and the bowel and bile ducts can spasm. Polysaccharides are not easily absorbed from the digestive tract, but may produce a laxative effect. Larger doses may produce intestinal or stomach blockage.		
Skin Contact	Skin contact is not thought to have harmful health effects (as classified under EC Directives); the material may still produce health damage following entry through wounds, lesions or abrasions. There is some evidence to suggest that the material may cause mild but significant inflammation of the skin either following direct contact or after a delay of some time. Repeated exposure can cause contact dermatitis which is characterised by redness, swelling and blistering. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.		
Eye	Although the material is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).		
Chronic	Repeated or long-term occupational exposure is likely to produce cumulative health effects involving organs or biochemical systems. Chronic morphine poisoning or addiction causes pin-point pupils, rapid mood changes and poor social adaptation. As dependence and tolerance occurs, there is an overwhelming need to continue taking the drug or similar drugs and to increase the dose. Studies indicate that diets containing large amounts of non-absorbable polysaccharides, such as cellulose, might decrease absorption of calcium, magnesium, zinc and phosphorus.		
Proladone®, Oxycodone 30mg	тохісіту	IRRITATION	
Suppositories	Not Available	Not Available	
alpha-lactose	TOXICITY Oral (rat) LD50: >10000 mg/kg ^[2]	IRRITATION Not Available	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
starch	Not Available	Skin (human): 0.3 mg/3d-l mild	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
pectin	Not Available	Not Available	
	тохісіту	IRRITATION	
Oxycodone	Not Available	Not Available	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
magnesium stearate	Not Available	Not Available	

Legend:	1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances		
	uala extracted from RTECS - Register of Toxic Effect of C	nennicai Substances	
ALPHA-LACTOSE	Equivocal tumorigenic agent by RTECS criteria.		
OXYCODONE	WARNING: Abuse can lead to habituation. Subject to Federal and State Regulations. Narcotic Substance, Schedule I (UN).		
MAGNESIUM STEARATE	Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production. Fatty acid salts of low acute toxicity. Their potential to irritate the skin and eyes is dependent on chain length.		
Proladone®, Oxycodone 30mg Suppositories & STARCH	The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesicles, scaling and thickening of the skin.		
Acute Toxicity	\odot	Carcinogenicity	\odot
Skin Irritation/Corrosion	0	Reproductivity	\odot
Serious Eye Damage/Irritation	0	STOT - Single Exposure	0
Respiratory or Skin sensitisation	0	STOT - Repeated Exposure	*
Mutagenicity	0	Aspiration Hazard	0
		✓ - L	Data available but does not fill the criteria for classification Data available to make classification Data Not Available to make classification

SECTION 12 ECOLOGICAL INFORMATION

Toxicity ENDPOINT **TEST DURATION (HR)** SPECIES VALUE SOURCE Proladone®, Oxycodone 30mg Not Not Not Suppositories Not Available Not Available Available Available Available ENDPOINT TEST DURATION (HR) SPECIES VALUE SOURCE alpha-lactose Not Not Not Not Available Not Available Available Available Available ENDPOINT TEST DURATION (HR) SPECIES VALUE SOURCE starch Not Not Not Not Available Not Available Available Available Available TEST DURATION (HR) ENDPOINT SPECIES VALUE SOURCE pectin Not Not Not Not Available Not Available Available Available Available ENDPOINT TEST DURATION (HR) SPECIES VALUE SOURCE Oxycodone Not Not Not Not Available Not Available Available Available Available TEST DURATION (HR) ENDPOINT SPECIES VALUE SOURCE magnesium stearate Not Not Not Not Available Not Available Available Available Available Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 Legend:

Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
alpha-lactose	LOW	LOW
Oxycodone	HIGH	HIGH

Bioaccumulative potential

Ingredient	Bioaccumulation
alpha-lactose	LOW (LogKOW = -5.1249)

Version No: 3.1.1.1

Proladone®, Oxycodone 30mg Suppositories

LOW (LogKOW = -0.138)
Mobility
LOW (KOC = 10)
LOW (KOC = 10)

SECTION 13 DISPOSAL CONSIDERATIONS

roduct / Packaging disposal	 DO NOT allow wash water from cleaning or process equipment to enter drains. It may be necessary to collect all wash water for treatment before disposal. In all cases disposal to sever may be subject to local laws and regulations and these should be considered first. Where in doubt contact the responsible authority. Valuable substance, hold all residues for recovery. Disposal of the material must be carried out in accordance with the requirements of the relevant Federal/State Act(s) or Code(s) regulating the disposal of Drugs of Addiction. Consult manufacturer/supplier for recycling options. Decontaminate empty containers with water; incinerate plastic bags. DO NOT reuse containers. Bury empty containers in an authorised landfill. Recycle wherever possible or consult manufacturer for recycling options. Consult State Land Waste Authority for disposal. Bury or incinerate residue at an approved site.
	Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 TRANSPORT INFORMATION

Labels Required

Marine Pollutant	NO	
HAZCHEM	Not Applicable	

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

ALPHA-LACTOSE(63-42-3) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Inventory of Chemical Substances (AICS)

STARCH(9005-25-8) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Exposure Standards

Australia Inventory of Chemical Substances (AICS)

Australia Inventory of Chemical Substances (AICS)

PECTIN(9000-69-5) IS FOUND ON THE FOLLOWING REGULATORY LISTS Australia Inventory of Chemical Substances (AICS)

OXYCODONE(76-42-6) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Inventory of Chemical Substances (AICS)

MAGNESIUM STEARATE(557-04-0) IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Exposure Standards

National Inventory	Status
Australia - AICS	Y
Canada - DSL	N (Oxycodone)
Canada - NDSL	N (alpha-lactose; magnesium stearate; pectin; Oxycodone)
China - IECSC	N (Oxycodone)
Europe - EINEC / ELINCS / NLP	Υ
Japan - ENCS	N (pectin; Oxycodone)
Korea - KECI	N (Oxycodone)
New Zealand - NZIoC	N (Oxycodone)
Philippines - PICCS	N (Oxycodone)
USA - TSCA	N (Oxycodone)
Legend:	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16 OTHER INFORMATION

Other information

Ingredients with multiple cas numbers

Name	CAS No
alpha-lactose	63-42-3, 5989-81-1, 14641-93-1, 64044-51-5, 10039-26-6
starch	9005-25-8, 65996-63-6, 68441-21-4, 9005-84-9

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC – TWA: Permissible Concentration-Time Weighted Average PC – STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure Limit. IDLH: Immediately Dangerous to Life or Health Concentrations OSF: Odour Safety Factor NOAEL: No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level LOD: Limit Of Detection OTV: Odour Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Phebra and the Phi symbol are trademarks of Phebra Pty Ltd, 19 Orion Road, Lane Cove West, Australia.

Proladone is a register trademark of Abbott GmbH.

